Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed follicular lymphoma~* CD20+ at time of diagnosis or subsequently~* More than 4 weeks since prior rituximab~* More than 3 weeks since prior anticancer therapy (6 weeks for nitrosourea or mitomycin C)~* More than 4 weeks since prior major surgery~* More than 2 weeks since prior investigational drugs~Exclusion Criteria:~* AIDS-related lymphoma~* History or evidence of CNS involvement~* Pregnant or nursing~* known HIV positivity~* serious medical or psychiatric illness that would preclude study participation~* myocardial infarction within the past 6 months~* congestive heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia or active conduction system abnormalities~* known hypersensitivity to rituximab, bortezomib, boron, or mannitol~* prior autologous or allogeneic stem cell transplantation~* prior radioimmunoconjugate therapy or prior exposure to murine antibodies~* prior external-beam irradiation to \> 25% of active bone marrow

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bortezomib, Ibritumomab tiuxetan, rituximab (Type: EXPERIMENTAL): Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).